Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy by Sarno, L. et al.
Prospective screening for trisomies by cell-free DNA testing of maternal blood in first 
trimester twin pregnancies 
 
Laura Sarno,1 Rocio Revello,1 Ele Hanson,1 Ranjit Akolekar,1,2 KH Nicolaides,1,2 
 
1. Harris Birthright Research Centre of Fetal Medicine, King’s College Hospital, London, UK 
2. Department of Fetal Medicine, Medway Maritime Hospital, Kent. 
 
 
Running head: Cell free DNA testing in twins 
 
Key words: Cell-free DNA, Twin pregnancies, First trimester Screening, Trisomy 21, Fetal 
fraction, Non-invasive prenatal testing 
 
 
Acknowledgement: The study was supported by a grant from The Fetal Medicine 
Foundation (UK Charity No: 1037116). The cost of collection and analysis of some of the 
samples was covered by Ariosa Diagnostics, Inc. San Jose, CA, USA. 
 
 
 
Correspondence 
Professor KH Nicolaides  
Harris Birthright Research Centre for Fetal Medicine 
King's College Hospital 
Denmark Hill 
London SE5 9RS   
Tel: 00 44 2032998256 
Fax: 00 44 2032993898  
Mail: kypros@fetalmedicine.com 
ABSTRACT 
 
Objectives: First, to examine the performance of screening for fetal trisomies 21, 18 and 13 
in twin pregnancies by cell-free (cf) DNA testing of maternal blood and second, to compare 
twin and singleton pregnancies for the distribution of fetal fraction and failure rate to obtain a 
result. 
 
Methods: This was a prospective study in 438 twin and 10,698 singleton pregnancies 
undergoing screening for fetal trisomies by cfDNA testing at 10+0-13+6 weeks’ gestation. 
Chromosome-selective sequencing of cfDNA was used and in twin pregnancies an algorithm 
was applied that relies on the lower fetal fraction contribution of the two fetuses. Multivariate 
regression analysis was used to determine significant predictors of fetal fraction and failed 
result. 
 
Results: In twin pregnancies, compared to singletons, the median fetal fraction was lower 
(8.0, IQR 6.0-10.4% vs 11.0, IQR 8.3-14.4%; p<0.0001) and failure rate after first sampling 
was higher (9.4% vs 2.9%; p<0.0001). Multivariate logistic regression analysis demonstrated 
that the risk of test failure increased with increasing maternal age and body mass index and 
decreased with fetal crown-rump length; the risk was increased in women of South Asian 
racial origin and in pregnancies conceived by in vitro fertilization. The main contributor to the 
higher rate of failure in twins was conception by in vitro fertilization which was observed in 
9.5% of singletons and 56.2% of twins. In the 417 twin pregnancies with a cfDNA result after 
first or second sampling, the detection rate was 100% for trisomy 21 (8 of 8) and 60% for 
trisomy 18 or 13 (3 of 5), at false positive rate of 0.25% (1 of 404). In the 10,530 singleton 
pregnancies with a cfDNA result after first or second sampling, the detection rate was 98.7% 
for trisomy 21 (156 of 158) and 80.3% for trisomy 18 or 13 (49 of 61), at false positive rate of 
0.22% (23 of 10,311).   
 
Conclusions: In twin pregnancies, compared to singletons, undergoing first trimester 
screening for trisomies by cfDNA testing, the fetal fraction is lower and failure rate higher. 
The number of trisomic twin pregnancies examined is too small for accurate assessment of 
performance of screening, but this may be similar to that in singleton pregnancies. 
  
INTRODUCTION 
 
In singleton pregnancies, cell-free (cf) DNA analysis of maternal blood provides effective 
screening for trisomies 21, 18 and 13. A meta-analysis of clinical validation and 
implementation studies in large numbers of affected and unaffected pregnancies reported 
that the detection rate (DR) and false positive rate (FPR) for trisomy 21 were 99.2% (95% 
CI, 98.5–99.6%) and 0.09% (95% CI, 0.05–0.14%), and the respective values for trisomy 18 
were 96.3% (95% CI, 94.3–97.9%) and 0.13% (95% CI, 0.07–0.20) and for trisomy 13 were 
91.0% (95% CI, 85.0–95.6%) and 0.13% (95% CI, 0.05–0.26%) 1. In contrast to singleton 
pregnancies where there is extensive data on the performance of screening for trisomies by 
cfDNA testing, very few studies reported data on twins 2-7; most studies were retrospective 
on stored plasma samples or prospective but with incomplete follow up 2-5. There are only 
two studies that examined twin pregnancies prospectively and reported outcome in all cases; 
in their combined data from 201 cases at 11-36 weeks’ gestation, they correctly classified all 
10 cases of trisomy 21, one of two cases of trisomy 18 and the FPR was 0% in the 189 
cases with euploid fetuses 6,7. Consequently, the results are promising but the number of 
examined cases is too small for accurate assessment of performance of screening. 
 
In cfDNA testing the ability to detect the small increase in the amount of a given chromosome in 
maternal plasma in a trisomic compared to a disomic pregnancy is directly related to the relative 
proportion of the fetal to maternal origin of the cfDNA 8.  When the fetal fraction is low, it is more 
difficult to discriminate between trisomic and unaffected pregnancies and a minimum fraction of 
about 4% is usually necessary for accurate cfDNA analysis; companies that routinely measure 
fetal fraction report a failed result when the fraction is below 4%. In twin pregnancies, cfDNA 
testing is more complex than in singleton pregnancies, because if the two fetuses are dizygotic 
only one is likely to have aneuploidy when present. Since in dizygotic twins each fetus can 
contribute different amounts of cfDNA into the maternal circulation 9,10, if the fetal fraction of a 
trisomic fetus is below the threshold of 4% but there is a high contribution from the disomic co-
twin so that there is a satisfactory total fetal fraction a false negative result could be obtained. To 
avoid this potential mistake it was proposed that in cfDNA testing in twin pregnancies the lower 
fetal fraction of the two fetuses, rather than the total, should be estimated in the assessment of 
risk for aneuploidies 11. An inevitable consequence of such policy is that the failure rate of the 
cfDNA test in twin pregnancies is higher than in singletons 3,5. 
 
The objectives of this prospective study are first, is to examine the performance of cfDNA 
screening for fetal trisomies 21, 18 and 13 in twin pregnancies and second, to compare twin 
and singleton pregnancies for the distribution of fetal fraction and failure rate to obtain a 
result. 
 
 
METHODS 
 
The data for this study were derived from first, cfDNA testing as an option following first-
trimester combined testing in women with singleton or twin pregnancies attending for routine 
care at 11+0-13+6 weeks’ gestation in one of two National Health Service (NHS) hospitals in 
England 12 and second, cfDNA testing as part of routine screening in pregnancies at 10+0-
13+6 weeks attending the Fetal Medicine Centre in London, which is a private clinic 13. The 
patients were examined between October 2012 and August 2015. 
 
We recorded maternal characteristics and medical history, including maternal age, racial 
origin (Caucasian, African, South Asian, East Asian and mixed), method of conception 
(natural or assisted conception requiring the use of ovulation drugs or in-vitro fertilization), 
cigarette smoking during pregnancy (yes or no) and parity (parous or nulliparous if no 
previous pregnancy at or after 24 weeks’ gestation). We also measured maternal weight and 
height. In all cases free ß-hCG and PAPP-A were measured within 10 minutes of blood 
collection at 10+0-13+6 weeks (DELFIA Xpress system, PerkinElmer Life and Analytical 
Sciences, Waltham, USA, or Kryptor, Thermo Scientific, Berlin, Germany). An ultrasound 
scan was carried out at 11+0-13+6 weeks to determine gestational age from the measurement 
of the fetal crown-rump length (CRL) 14, diagnose any major fetal abnormalities and measure 
fetal nuchal translucency (NT) thickness. In twin pregnancies, gestational age was 
determined from the CRL of the larger fetus and chorionicity was determined by examining 
the junction of the intertwin membrane with the placenta 15. The measured NT was 
expressed as a difference from the expected normal mean for gestation (delta value) 16. 
Similarly, the measured free ß-hCG and PAPP-A were converted into multiple of the median 
(MoM) for gestational age adjusted for maternal weight, racial origin, smoking status, method 
of conception, parity, chorionicity and machine for the assays 17,18. Biophysical and 
biochemical markers were combined to estimate the patient-specific risk for trisomies 21, 18 
and 13. 
 
Women provided written informed consent and maternal blood (20 mL) was sent via courier 
to the USA for cfDNA testing (HarmonyTM Prenatal Test, Ariosa Diagnostics, Inc., San Jose, 
CA) 19,20. Chromosome-selective sequencing, referred to as digital analysis of selected 
regions (DANSR), and fetal-fraction optimized risk of trisomy evaluation (FORTE) were used 
to assay non-polymorphic and polymorphic loci, where fetal alleles differ from maternal 
alleles, enabling simultaneous determination of chromosome proportion and fetal fraction. In 
twin pregnancies the FORTETM algorithm used for singletons was modified so that the 
smallest fetal fraction contribution of the two fetuses was considered 11. Risk scores for 
trisomy 21, 18, and 13 were provided as a percentage with ranges capped at >99% and 
<0.01%.  
  
In cases where the cfDNA test did not provide results the parents were offered repeat testing 
or to rely on the results of the combined test in deciding whether to have an invasive test or 
not. In cases with a high-risk result from the cfDNA test, the parents were advised to 
consider having invasive fetal karyotyping before deciding on the further management of 
their pregnancy.  
 
Patient characteristics and results of the investigations were recorded in a fetal database. 
Results from invasive testing, obtained from laboratories, and pregnancy outcome, obtained 
from obstetricians, general practitioners or the patients, were recorded in the same 
database. The outcomes were divided into firstly, trisomy 21, 18 or 13 if the karyotype of 
chorionic villi, amniotic fluid or neonatal blood demonstrated the relevant trisomy, secondly, 
no trisomy 21, 18 or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood was 
normal or the neonate was phenotypically normal, thirdly, no known karyotype because the 
pregnancies resulted in miscarriage or stillbirth and no karyotyping of fetal tissue was carried 
out, and fourthly, outcome unknown because the pregnancies were lost to follow up. 
 
Statistical analyses 
 
Descriptive data were presented in median and interquartile range (IQR) for continuous 
variables and in numbers and percentages for categorical variables. The measured fetal 
fraction was log10 transformed to make the distribution Gaussian, which was assessed using 
histograms and probability plots. In the combined data of singleton and twin pregnancies and  
separately in the twin pregnancies, univariate and multivariate regression analysis were 
used to determine which of the factors amongst maternal age, body mass index, racial 
origin, smoking status, method of conception, fetal CRL, serum PAPP-A and free ß-hCG, 
fetal NT and fetal karyotype were significant predictors of log10 fetal fraction. Similarly, in the 
combined data of singleton and twin pregnancies and separately in the twin pregnancies, 
logistic regression analysis was undertaken to examine the maternal and pregnancy 
characteristics providing significant contribution to prediction of failed cfDNA test result after 
first sampling. 
 The statistical software package SPSS 21.0 (SPSS Inc.,Chicago, IL) was used for data 
analyses. 
 
 
RESULTS 
 
Characteristics of study population 
 
A total of 467 twin pregnancies had cfDNA testing and combined screening for trisomies, but 
29 (6.2%) of these were excluded from further analysis either because the pregnancies 
ended in termination, miscarriage or stillbirth with no known karyotype (n=23), they were lost 
to follow up (n=4) or they had chromosomal abnormalities other than trisomies 21, 18 or 13 
(n=2). In the 438 cases included in the study, 373 (85.2%) were dichorionic and 65 (14.8%) 
were monochorionic. Maternal and pregnancy characteristics of the 438 twin pregnancies 
from this study and 10,698 from a previous study in singleton pregnancies 21, are 
summarized in Table 1.  
 
The 438 twin pregnancies included 8 cases of trisomy 21, 4 of trisomy 18, 1 of trisomy 13 
and 425 unaffected cases. The 10,698 singleton pregnancies included 160 cases of trisomy 
21, 50 of trisomy 18, 16 of trisomy 13 and 10,472 unaffected by these trisomies 21.  
 
Performance of screening 
 
In the 417 twin pregnancies with a cfDNA result after first or second sampling, the detection 
rate was 100% for trisomy 21 (8 of 8), 75% for trisomy 18 (3 of 4) and 0% for trisomy 13 (0 of 
1), at false positive rate of 0.25% (1 of 404).  All trisomic pregnancies were dichorionic with 
one affected and one normal twin. 
 
In the 10,530 singleton pregnancies with a cfDNA result after first or second sampling, the 
detection rate was 98.7% for trisomy 21 (156 of 158), 89.1% for trisomy 18 (41 of 46) and 
53.3% for trisomy 13 (8 of 15), at false positive rate of 0.22% (23 of 10,311).   
 
Factors affecting fetal fraction in singleton and twin pregnancies 
 
The distribution of log10 fetal fraction from first sampling was Gaussian in both the singleton 
and twin pregnancies (Figure 1), but the median fetal fraction in twins was lower than in 
singletons (8.0, IQR 6.0-10.4% vs 11.0, IQR 8.3-14.4%; p<0.0001); in these calculations, it 
was assumed that in the cases of failed result, the fetal fraction was 3%. 
 
In the combined data from singleton and twin pregnancies, multivariate logistic regression 
analysis demonstrated that the fetal fraction increased with increasing fetal CRL, PAPP-A 
and free β-hCG MoM and decreased with increasing maternal age and body mass index, 
and it was lower in twin pregnancies than in singletons and decreased in women of South 
Asian racial origin and in pregnancies achieved by in vitro fertilization (Supplementary Table 
1) 
 
In twin pregnancies, multivariate logistic regression analysis demonstrated that the fetal 
fraction increased with increasing PAPP-A and free β-hCG MoM and decreased with 
increasing maternal body mass index. The fetal fraction was higher in monochorionic than 
dichorionic twins (median 10.1, IQR 7.6-14.5% vs median 7.7, IQR 5.8-10.0%; p<0.0001) 
and it was decreased in pregnancies achieved by in vitro fertilization (Supplementary Table 
2). 
 
Factors affecting cfDNA test failure in singleton and twin pregnancies 
 
There was no result from cfDNA testing after first sampling in 2.9% (316 of 10,698) singleton 
pregnancies and in 9.4% (41 of 438) twin pregnancies (p<0.0001). In the 41 twin 
pregnancies with failed cfDNA testing after first sampling, 39 patients had repeat cfDNA 
testing and this provided results in 20 (51.3%) cases. In the 316 singleton pregnancies with 
failed cfDNA testing after first sampling, 235 patients had repeat cfDNA testing and this 
provided results in 148 (63.0%) cases 21.  
 
In the combined data from singleton and twin pregnancies, multivariate logistic regression 
analysis demonstrated that risk of test failure after first sampling increased with increasing 
maternal age and body mass index and decreased with fetal CRL. The risk was higher in 
twin pregnancies than in singletons and increased in women of South Asian racial origin and 
in pregnancies achieved by in vitro fertilization (Table 2). The relation of test failure to body 
mass index and method of conception in singleton and twin pregnancies is illustrated in 
Figure 2 and reported in supplementary Table 3. 
 
In twin pregnancies, multivariate logistic regression analysis demonstrated that risk of test 
failure after first sampling increased with increasing body mass index, decreased with fetal 
CRL and was increased in pregnancies achieved by in vitro fertilization (Table 3). 
 
 
DISCUSSION 
 
Principal findings of the study  
 
This prospective study demonstrates the feasibility of chromosome-selective sequencing of 
cfDNA in maternal blood for the assessment of risk for fetal trisomies 21, 18 and 13 in twin 
pregnancies at 10-13 weeks’ gestation. In twin pregnancies, compared to singletons, the 
median fetal fraction was lower (8 vs 11%) and the failure rate after first sampling was three 
times higher (9.4 vs 2.9%). In those with a failed test, repeat testing provided a result in 51% 
of twins and in 63% of singletons. The reason for the lower fetal fraction and higher failure 
rate in twins, compared to singletons, is the inevitable consequence of selecting the lower 
fetal fraction of the two fetuses rather than the total in estimating the risk for aneuploidies 11. 
The rationale for this choice is to avoid a false negative result in a dizygotic twin pregnancy 
discordant for aneuploidy where the total fetal fraction is satisfactory but the contribution of 
the affected fetus could be less than 4%. 
 
In both singleton and twin pregnancies, the main contributors to low fetal fraction and high 
failure rate are high maternal body mass index, conception by in vitro fertilization, low fetal 
CRL and low serum free -hCG and PAPP-A. The main factor for the higher rate of failure in 
twins was conception by in vitro fertilization which was observed in 9.5% of our singleton and 
56.2% of our twin pregnancies. The source of fetal cfDNA in maternal plasma is dying cells 
in the placenta and the observed associations between fetal fraction and fetal CRL and 
serum free -hCG and PAPP-A are likely to be the consequence of placental mass. The 
inverse association between fetal fraction and maternal weight could be attributed to a 
dilutional effect. Low fetal fraction in conceptions by in vitro fertilization could be the 
consequence of the associated inpaired placentation; in such pregnancies the serum 
concentration of PAPP-A is decreased by 10-25% 17,22,23 and the incidence of preeclampsia 
is increased 24,25. 
 
The performance of screening for trisomies by cfDNA testing in our twin pregnancies was similar 
to that in singletons. However, the number of trisomic fetuses was too small for definite 
conclusions to be drawn. 
 
Comparison of findings to those in previous studies 
 
Screening for trisomies in twin pregnancies by cfDNA testing has been carried out by massively 
parallel shotgun sequencing (MPSS) or by chromosome-selective sequencing. The MPSS 
studies examined stored plasma or prospectively collected blood from a combined total of 
280 twin pregnancies 2,4,6,7. In these studies no attempt was made to determine the fetal 
fraction for each twin and it was assumed that the contribution from each fetus to the 
maternal plasma cfDNA was adequate for accurate results. The cfDNA test provided results 
for all cases, the DR was 100% (23 of 23) for trisomy 21, 67% (2 of 3) for trisomy 18 or 13 
and the FPR was 0% (0 of 254). 
 
One previous study used chromosome-selective sequencing and an algorithm that relies on 
the lower fetal fraction of the twins, as in the present study, to assess risk for trisomies in 
either stored plasma samples or prospectively in blood obtained at 11-13 weeks’ gestation 3. 
In the retrospective study, the DR was 90% (9 of 10) for trisomy 21, 100% for trisomy 13 (1 
of 1) and the FPR was 0% (0 of 181). In the prospective study in 68 twin pregnancies, which 
are included in the current study, there was test failure of 13.2% after first sampling and this 
was reduced to 7.4% after second sampling. Both cases of trisomy 21 and the one case of 
trisomy 18 were detected at FPR of 0% (0 of 60); although at the time of publication most 
euploid pregnancies were continuing they have now delivered and the result of the cfDNA 
test was correct. 
 
One multicenter study, which included some of the data in the current study, used 
chromosome-selective sequencing for cfDNA testing in 515 twin pregnancies at 10-28 
weeks’ gestation 5. The objective of the study was to compare the failure rate in twin 
pregnancies with that of 1,847 singleton pregnancies; in twins the failure rate after first 
sampling was higher (5.6 vs 1.7%) and the main contributors to test failure were increased 
maternal weight and conception by in vitro fertilization. 
 
In the combined data from the MPSS studies and the current one, results from cfDNA testing 
have been reported in a total of 697 twin pregnancies with known outcome, the DR was 
100% (31 of 31) for trisomy 21, 63% (5 of 8) for trisomy 18 or 13 and the FPR was 0.15% (1 
of 658). 
 
Implication for clinical practice 
 
Monochorionic twins are monozygotic and do not pose any special problems in relation to 
cfDNA testing, invasive testing or subsequent management of possible trisomies; the fetal 
fraction is similar to that in singleton pregnancies, if the parents wish invasive testing this can 
easily be carried in the first trimester allowing for the option of early pregnancy termination if 
this is the parental choice following diagnosis of trisomies in both fetuses.  
 
In contrast, dichorionic twins are usually dizogotic and they pose major challenges in 
screening and diagnosis of trisomies and subsequent management of pregnancies 
discordant for such aneuploidies. In the last 20 years the rate of twinning has increased, 
mainly due to the increasing maternal age of the population and the widespread use of in 
vitro fertilization. The consequence of increased maternal age is that the proportion of twin 
pregnancies that are screen positive by the traditional methods of screening is considerably 
higher than in singleton pregnancies. The consequence of increased conception by in vitro 
fertilization is the high risk of cfDNA test failure. It could be argued that in twin pregnancies 
conceived by in vitro fertilization in women with high body mass index and identified by 
traditional screening as being at high risk for trisomies it would be preferable to select 
invasive testing rather than the cfDNA test. If the pregnancies are discordant for an 
aneuploidy and the parents choose to have selective fetocide, the subsequent risk of 
miscarriage or early preterm birth increase with gestational age at fetocide 26. The high 
failure rate of cfDNA testing would shift the option of prenatal diagnosis and selective 
fetocide from the first to the second trimester with consequent increase in the rate of 
miscarriage. The counter argument is that the risk of miscarriage from invasive testing in 
twins is likely to be higher than in singletons and many older women conceiving by in vitro 
fertilization would be reluctant to select invasive testing unless their risk from traditional 
screening is very high. 
 
Conclusions 
 
Screening by cfDNA testing of maternal blood in twin pregnancies, has a similarly high DR 
for trisomy 21 and low FPR as in singleton pregnancies. The number of cases of trisomies 
18 and 13 examined is very small for reliable conclusions to be drawn. Chromosome-
selective sequencing with estimation of fetal fraction from each twin, which aims to minimize 
the risk of providing false negative results by ensuring that the lower of the two is at least 
4%, is associated with a higher failure rate than methods which do not measure fetal fraction 
or ignore assessment of the contribution of each fetus. In twin pregnancies, as in singletons, 
the main contributors to test failure of chromosome-selective sequencing are increased 
maternal weight and conception by in vitro fertilization. 
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Figure legend 
 
Figure 1. Frequency distribution of log10 fetal fraction in maternal blood cfDNA in singleton 
(top) and twin (bottom) pregnancies.  
 
Figure 2. Failure rate of cell-free DNA testing (%) plotted against maternal body mass index 
in singleton (solid lines) and twin (dotted lines) pregnancies with conception by in vitro 
fertilization (red lines) or spontaneously or through ovulation induction (blue lines). In these 
estimates it was assumed that maternal age was 35 years, the racial origin was Caucasian 
and the fetal crown-rump length was 55 mm. 
  
Table 1. Maternal and pregnancy characteristics of the study population. 
 
Maternal and pregnancy characteristic 
Singleton 
(n=10,698) 
Twin 
(n=438) 
Maternal age in years, median (IQR) 36.3 (33.2-39.3) 37.3 (34.6-40.0)*** 
Maternal body mass index in kg/m2, median (IQR) 23.3 (21.1-26.5) 23.5 (21.0-26.9) 
Racial origin   
   Caucasian, n (%) 8,751 (81.8) 358 (81.7) 
   African, n (%) 698 (6.5) 26 (5.9) 
   South Asian, n (%) 663 (6.2) 30 (6.8) 
   East Asian, n (%) 386 (3.6) 19 (4.3) 
   Mixed, n (%) 200 (1.9) 5 (1.1) 
Parity   
   Nulliparous, n (%) 4,760 (44.5) 261 (59.6)*** 
Cigarette smoker, n (%) 263 (2.5) 3 (0.7)** 
Conception   
   Spontaneous or ovulation induction, n (%) 9683 (90.5) 192 (43.8) 
   In vitro fertilization, n (%) 1015 (9.5) 246 (56.2)*** 
     Origin of oocyte   
         Self 904 (89.1) 216 (87.8) 
         Donor 111 (10.9) 30 (12.2) 
Gestation at sampling, median (IQR) 11.9 (10.6-12.9) 11.7 (10.4-12.9)* 
Crown-rump length in mm, median (IQR) 53.7 (38.5-65.7) 54.2 (38.9-66.3) 
 
IQR = interquartile range; CRL = crown-rump length; Significance value * p<0.05; ** p<0.01; 
*** p<0.0001 
 Table 2. Univariate and multivariate logistic regression analysis demonstrating factors from 
maternal and pregnancy characteristics providing significant contribution to prediction of 
failed cfDNA testing 
 
 
CI = confidence interval; CRL = crown-rump length; MoM = multiple of the median; NT = 
nuchal translucency 
 
  
Independent variable 
Univariate analysis Multivariate analysis 
Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
Constant   -8.470 <0.0001 
Age in years 1.051 (1.026-1.076) <0.0001 1.031 (1.007-1.055) 0.011 
Body mass index, kg/m2 1.138 (1.121-1.155) <0.0001 1.174 (1.154-1.194) <0.0001 
Race origin     
   Caucasian  (Reference) <0.0001   
   African 1.915 (1.356-2.705) <0.0001   
   South Asian 2.006 (1.420-2.834) <0.0001 1.851 (1.284-2.669) 0.001 
   East Asian 0.592 (0.277-1.262) 0.174   
   Mixed 1.561 (0.791-3.079) 0.199   
Smoking 0.692 (0.306-1.564) 0.376   
In vitro fertilization 5.702 (4.572-7.110) <0.0001 6.487 (5.009-8.401) <0.0001 
Fetal CRL in mm 0.991 (0.983-0.998) 0.009 0.985 (0.977-0.993) <0.0001 
Pregnancy type     
    Singleton pregnancy (Reference) <0.0001   
    Twin pregnancy 3.393 (2.414-4.769) <0.0001 1.477 (1.006-2.170) 0.040 
Table 3. Estimated rate of failure of cell-free DNA (cfDNA) testing in singleton and twin 
pregnancies stratified according to method of conception in women with a body mass index 
from 15 to 60 kg/m2 given a fixed maternal age of 35 years, Caucasian racial origin and a 
fetal crown-rump length of 55 mm. 
 
BMI 
(kg/m2) 
Rate of failure of cell free DNA testing [% (95%CI)] 
Singleton pregnancy Twin pregnancy 
Spontaneous IVF Spontaneous IVF 
15 0.3 (0.2-0.4) 1.9 (1.6 - 2.2) 0.4 (0.3 - 0.5) 2.7 (2.4 - 3) 
16 0.3 (0.2-0.4) 2.2 (1.9 - 2.5) 0.5 (0.4 - 0.6) 3.2 (2.8 - 3.6) 
17 0.4 (0.3-0.5) 2.5 (2.2 - 2.8) 0.6 (0.4 - 0.8) 3.7 (3.3 - 4.1) 
18 0.5 (0.4-0.6) 3.0 (2.6 - 3.4) 0.7 (0.5 - 0.9) 4.3 (3.9 - 4.7) 
19 0.6 (0.4-0.8) 3.5 (3.1 - 3.9) 0.8 (0.6 – 1.0) 5.0 (4.5 - 5.5) 
20 0.6 (0.4-0.8) 4.0 (3.6 - 4.4) 1.0 (0.8 - 1.2) 5.9 (5.4 - 6.4) 
21 0.8 (0.6-1.0) 4.7 (4.3 - 5.1) 1.1 (0.9 - 1.3) 6.8 (6.3 - 7.3) 
22 0.9 (0.7-1.1) 5.5 (5.0 – 6.0) 1.3 (1.1 - 1.5) 7.9 (7.3 - 8.5) 
23 1.0 (0.8-1.2) 6.4 (5.9 - 6.9) 1.5 (1.2 - 1.8) 9.1 (8.5 - 9.7) 
24 1.2 (1.0-1.4) 7.4 (6.9 - 7.9) 1.8 (1.5 - 2.1) 10.6 (10 - 11.2) 
25 1.4 (1.2-1.6) 8.6 (8.0 - 9.2) 2.1 (1.8 - 2.4) 12.2 (11.5 - 12.9) 
26 1.7 (1.4-2.0) 9.9 (9.3 - 10.5) 2.5 (2.2 - 2.8) 14.0 (13.3 - 14.7) 
27 2.0 (1.7-2.3) 11.5 (10.8 - 12.2) 2.9 (2.6 - 3.2) 16.0 (15.2 - 16.8) 
28 2.3 (2.0-2.6) 13.2 (12.5 - 13.9) 3.3 (2.9 - 3.7) 18.3 (17.5 - 19.1) 
29 2.7 (2.4-3.0) 15.1 (14.4 - 15.8) 3.9 (3.5 - 4.3) 20.8 (20.0 - 21.6) 
30 3.1 (2.7-3.5) 17.3 (16.5 - 18.1) 4.6 (4.2 – 5.0) 23.6 (22.7 - 24.5) 
31 3.7 (3.3-4.1) 19.7 (18.9 - 20.5) 5.3 (4.8 - 5.8) 26.6 (25.7 - 27.5) 
32 4.3 (3.9-4.7) 22.4 (21.5 - 23.3) 6.2 (5.7 - 6.7) 29.9 (29.0 - 30.8) 
33 5.0 (4.5-5.5) 25.3 (24.4 - 26.2) 7.2 (6.7 - 7.7) 33.3 (32.3 - 34.3) 
34 5.8 (5.3-6.3) 28.4 (27.5 - 29.3) 8.3 (7.7 - 8.9) 37.0 (36.0 – 38.0) 
35 6.7 (6.2-7.2) 31.8 (30.8 - 32.8) 9.6 (9.0 - 10.2) 40.8 (39.8 - 41.8) 
36 7.8 (7.2-8.4) 35.4 (34.4 - 36.4) 11.1 (10.5 - 11.7) 44.7 (43.7 - 45.7) 
37 9.0 (8.4-9.6) 39.1 (38.1 - 40.1) 12.8 (12.1 - 13.5) 48.7 (47.7 - 49.7) 
38 10.4 (9.8-11.0) 43.0 (42.0 – 44.0) 14.7 (14.0 - 15.4) 52.7 (51.7 - 53.7) 
39 12.0 (11.3-12.7) 47.0 (46.0 – 48.0) 16.8 (16.0 - 17.6) 56.7 (55.7 - 57.7) 
40 13.8 (13.1-14.5) 51.0 (50.0 – 52.0) 19.1 (18.3 - 19.9) 60.6 (59.6 - 61.6) 
41 15.8 (15.0-16.6) 55.0 (54.0 – 56.0) 21.7 (20.8 - 22.6) 64.3 (63.3 - 65.3) 
42 18.1 (17.3-18.9) 58.9 (57.9 - 59.9) 24.6 (23.7 - 25.5) 67.9 (66.9 - 68.9) 
43 20.6 (19.8-21.4) 62.7 (61.7 - 63.7) 27.7 (26.8 - 28.6) 71.3 (70.4 - 72.2) 
44 23.3 (22.4-24.2) 66.4 (65.4 - 67.4) 31.0 (30.0 – 32.0) 74.5 (73.6 - 75.4) 
45 26.3 (25.4-27.2) 69.9 (69.0 - 70.8) 34.5 (33.5 - 35.5) 77.4 (76.5 - 78.3) 
46 29.5 (28.6-30.4) 73.1 (72.2 – 74.0) 38.3 (37.3 - 39.3) 80.1 (79.3 - 80.9) 
47 33.0 (32.0-34.0) 76.2 (75.3 - 77.1) 42.1 (41.1 - 43.1) 82.5 (81.7 - 83.3) 
48 36.6 (35.6-37.6) 78.9 (78.1 - 79.7) 46.1 (45.1 - 47.1) 84.7 (84.0 - 85.4) 
49 40.4 (39.4-41.4) 81.5 (80.7 - 82.3) 50.1 (49.1 - 51.1) 86.7 (86.0 - 87.4) 
50 44.3 (43.4-45.3) 83.8 (83.0 - 84.6) 54.0 (53.0 – 55.0) 88.4 (87.7 - 89.1) 
51 48.3 (47.3-49.3) 85.8 (85.1 - 86.5) 58.0 (57.0 – 59.0) 90.0 (89.4 - 90.6) 
52 52.3 (51.3-53.3) 87.7 (87.0 - 88.4) 61.8 (60.8 - 62.8) 91.3 (90.7 - 91.9) 
53 56.3 (55.3-57.3) 89.3 (88.7 - 89.9) 65.5 (64.5 - 66.5) 92.5 (92.0 – 93.0) 
54 60.2 (59.2-61.2) 90.7 (90.1 - 91.3) 69.1 (68.1 - 70.1) 93.5 (93.0 – 94.0) 
55 64.0 (63.0-65.0) 92.0 (91.4 - 92.6) 72.4 (71.5 - 73.3) 94.5 (94.0 – 95.0) 
56 67.6 (66.6-68.6) 93.1 (92.6 - 93.6) 75.5 (74.6 - 76.4) 95.2 (94.8 - 95.6) 
57 71.0 (70.1-71.9) 94.1 (93.6 - 94.6) 78.3 (77.4 - 79.2) 95.9 (95.5 - 96.3) 
58 74.2 (73.3-75.1) 94.9 (94.4 - 95.4) 80.9 (80.1 - 81.7) 96.5 (96.1 - 96.9) 
59 77.1 (76.2-78.0) 95.6 (95.2 – 96.0) 83.3 (82.5 - 84.1) 97.0 (96.6 - 97.4) 
60 79.8 (79.0-80.6) 96.3 (95.9 - 96.7) 85.4 (84.7 - 86.1) 97.4 (97.1 - 97.7) 
 
BMI= Body mass index; IVF = In vitro fertilization; CI = confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 1. Univariate and multivariate regression analysis demonstrating 
factors from maternal and pregnancy characteristics providing significant contribution to 
prediction of log10 transformed fetal fraction 
 
 
CI = confidence interval; CRL = crown-rump length; MoM = multiple of the median; NT = 
nuchal translucency 
  
Independent variable 
Univariate analysis Multivariate analysis 
Coefficient (95% CI) P value Coefficient (95% CI) P value 
Intercept   1.423 (1.394 to 1.452) <0.0001 
Age in years -0.002 (-0.003 to -0.001) <0.0001 -0.002 (-0.002 to -0.001) <0.0001 
Body mass index in kg/m2 -0.015 (-0.016 to -0.014) <0.0001 -0.015 (-0.016 to -0.014) <0.0001 
Race origin     
   Caucasian  (Reference)    
   African -0.055 (-0.070 to -0.040) <0.0001   
   South Asian -0.019 (-0.034 to -0.004) 0.013 -0.014 (-0.026 to -0.001) 0.034 
   East Asian 0.026 (0.006 to 0.045) 0.009   
   Mixed 0.009 (-0.018 to 0.036) 0.500   
Smoking 0.010 (-0.013 to 0.034) 0.400   
In vitro fertilization -0.107 (-0.119 to -0.096) <0.0001 -0.092 (-0.102 to -0.081) <0.0001 
Fetal CRL in mm 9.7e-05 (-1.4e-04 to 3.4e04) 0.423 0.001 (4.5e-04 to 0.001) <0.0001 
Pregnancy type     
    Singleton pregnancy (Reference)    
    Twin pregnancy -0.133 (-0.151 to -0.115) <0.0001 -0.091 (-0.108 to -0.075) <0.0001 
Delta nuchal translucency -0.009 (-0.015 to -0.004) 0.001   
Log10 PAPP-A MoM 0.160 (0.146 to 0.173) <0.0001 0.128 (0.116 to 0.140) <0.0001 
Log10 free β-hCG MoM 0.170 (0.157 to 0.182) <0.0001 0.138 (0.126 to 0.149) <0.0001 
Fetal karyotype     
     Euploid (Reference)    
     Trisomy 21 -0.006 (-035 to 0.024) 0.706   
     Trisomy 13/18 -0.156 (-0.201 to -0.111) <0.0001   
Supplementary Table 2. Univariate and multivariate regression analysis demonstrating 
factors from maternal and pregnancy characteristics providing significant contribution to 
prediction of log10 transformed fetal fraction in twin pregnancies 
 
 
CI = confidence interval; CRL = crown-rump length; MoM = multiple of the median; NT = 
nuchal translucency 
  
Independent variable 
Univariate analysis Multivariate analysis 
Coefficient (95% CI) P value Coefficient (95% CI) P value 
Intercept   1.182 (1.084 to 1.280) <0.0001 
Age in years -0.004 (-0.008 to -7.7e-05) 0.046   
Body mass index in kg/m2 -0.010 (-0.014 to -0.006) <0.0001 -0.011 (-0.015 to -0.007) <0.0001 
Race origin     
   Caucasian  (Reference)    
   African -0.035 (-0.115 to 0.046) 0.396   
   South Asian -0.040 (-0.115 to 0.035) 0.299   
   East Asian -0.054 (-0.147 to 0.039) 0.257   
   Mixed 0.017 (-0.161 to 0.195) 0.852   
Smoking -0.012 (-0.242 to 0.218) 0.918   
In vitro fertilisation -0.081 (-0.118 to -0.043) <0.0001 -0.065 (-0.100 to -0.029) <0.0001 
Origin of oocyte     
     Self (Reference)    
     Donor 0.032 (-0.050 to 0.114) 0.444   
Fetal CRL in mm 0.001 (-0.0002 to 0.002) 0.102   
Delta nuchal translucency -0.011 (-0.035-0.014) 0.388   
Chorionicity     
    Dichorionic (Reference)    
    Monochorionic 0.139 (0.088 to 0.191) <0.0001 0.118 (0.068 to 0.167) <0.0001 
Log10 PAPP-A MoM 0.137 (0.054 to 0.912) 0.001 0.133 (0.055 to 0.212) 0.001 
Log10 free β-hCG MoM 0.119 (0.048 to 0.190) 0.001 0.106 (0.039 to 0.173) 0.002 
Supplementary Table 3. Univariate and multivariate logistic regression analysis 
demonstrating factors from maternal and pregnancy characteristics providing significant 
contribution to prediction of failed cfDNA testing in twin pregnancies 
 
 
CI = confidence interval; CRL = crown-rump length; MoM = multiple of the median 
Independent variable 
Univariate analysis Multivariate analysis 
Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
Constant   -5.054 <0.0001 
Age in years 1.097 (1.017-1.184) 0.016   
Body mass index in kg/m2 1.093 (1.030-1.160) 0.003 1.142 (1.066-1.224) <0.0001 
Race origin     
   Caucasian  (Reference)    
   African 0.422 (0.055-3.220) 0.405   
   South Asian 2.110 (0.754-5.900) 0.155   
   East Asian 1.978 (0.546-7.163) 0.299   
   Mixed 2.637 (0.286-24.330) 0.392   
Smoking - -   
In vitro fertilization 3.563 (1.606-7.908) 0.002 3.898 (1.644-9.241) 0.002 
Origin of oocyte     
     Self (Reference)    
     Donor 0.992 (0.323-3.050) 0.989   
Fetal CRL in mm 0.974 (0.952-0.997) 0.027 0.971 (0.947-0.995) 0.020 
Chorionicity     
    Dichorionic (Reference)    
    Monochorionic 0.272 (0.064-1.155) 0.078   
